Reference Detail

Ref Type

Abstract

PMID

Authors

S. Pant D. Arnold J. Tabernero Y. Loriot G. Folprecht G.M. Haag D. Palmer H. Prenen J. Coward I. Lugowska J-C. Goeminne A. Cervantes M. Gutierrez H. Sweiti C. Hammond S. Najmi S. Thomas S. Triantos L. Crow M.H.H. Schuler

Title

1621P Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial

Journal	Vol	Issue	Date	Pages	Journal Short Title
Annals of Oncology	34	Supplement 2	October 2023

URL

https://www.annalsofoncology.org/article/S0923-7534(23)03407-5/fulltext

Abstract Text

Background Erdafitinib (erda) is an oral selective pan-FGFR tyrosine kinase inhibitor approved for treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3/2alt who have progressed during or after ≥1 line of platinum-based chemotherapy. Interim results from the RAGNAR study demonstrated tumor agnostic efficacy in patients (pts) with advanced solid tumors with predefined FGFRalt after failure of standard therapies (tx) (Loriot et al, ASCO 2022 ). Here we report results on pts with pancreatic cancer in RAGNAR. Methods Pts with advanced or metastatic pancreatic cancer with prespecified FGFR1-4alt (mutations or fusions), disease progression after ≥1 line of systemic tx, and who exhausted standard tx received oral erda until disease progression or intolerable toxicity. Primary end point is objective response rate (ORR) by independent review committee (IRC). Secondary endpoints include duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results At data cutoff (median survival f/u 15.24 mo), 18 pts with pancreatic cancer received erda. Median age was 60.5 y (range 34-78); 17 (94.4%) had visceral metastases; median 3 prior lines of systemic tx (range 1-9); 1 (5.6%) responded to last line of tx. All 18-pts had FGFR fusions (14 FGFR2, 4 FGFR1); none had FGFR mutations. None of the pts had KRAS co-alterations. ORR by IRC was 55.6% (95% CI 30.8-78.5). Median time to onset of response was 1.45 mo. Responses were observed in pts with FGFR1 and FGFR2 fusions. Median DCR was 94.4%. Median DOR, PFS and OS were 7.1 mo, 7.0 mo, and 19.7 mo respectively. Investigator-assessed efficacy data were comparable to IRC. The most common adverse events (AEs) were dry mouth (72%), diarrhea (67%), stomatitis (67%), dry skin (67%), hyperphosphatemia (56%), and fatigue (50%); 5 (28%) had serious AEs; 2 (11%) discontinued erda due to AEs. No treatment-related deaths were observed. Conclusions Erda demonstrated robust and clinically meaningful activity in pancreatic cancer pts with FGFRalt. Safety data were consistent with erda safety profile. Clinical trial identification NCT04083976.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References